Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 11/20 | 0.85 |
| ▸ | MAPT | P10636 | 3/20 | 0.85 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.85 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.85 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.85 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.85 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.85 |
| ▸ | GC | P02774 | 1/20 | 0.85 |
| ▸ | PGR | P06401 | 1/20 | 0.85 |
| ▸ | RXRA | P19793 | 1/20 | 0.85 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.85 |
| ▸ | CNR1 | P21554 | 1/20 | 0.85 |
| ▸ | HTR2C | P28335 | 1/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.85 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.85 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.85 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.85 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.85 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14005554 | 1.00 | VDR (0.85) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL16357615 | 1.00 | VDR (0.85) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL3680461 | 1.00 | VDR (0.85) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL3060963 | 1.00 | VDR (0.85) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL14489389 | 1.00 | VDR (0.85) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL14005545 | 1.00 | VDR (0.85) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL3219460 | 1.00 | VDR (0.85) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL14005553 | 1.00 | VDR (0.85) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL14029982 | 1.00 | VDR (0.85) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL13392195 | 0.94 | VDR (0.77) | VDRMAPTADORA3SLC6A2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024227063-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, SKIN DISORDERS, AND/OR EYE DISORDERS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-10-31 | — | — | WO | claimed |
| US-20220233641-A1 | Methods and Compositions for Treating Obesity and/or Skin Disorders | UNIV PENNSYLVANIA (US) | 2022-07-28 | — | — | US | claimed |
| EP-3969005-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY AND/OR SKIN DISORDERS | The Trustees of The University of Pennsylvania (US) | 2022-03-23 | — | — | EP | claimed |
| WO-2024227063-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, SKIN DISORDERS, AND/OR EYE DISORDERS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-10-31 | — | — | WO | disclosed |
| US-11752159-B2 | Compositions and methods for suppressing or reducing systemic immune response in a subject | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-09-12 | — | — | US | disclosed |
| US-20220233641-A1 | Methods and Compositions for Treating Obesity and/or Skin Disorders | UNIV PENNSYLVANIA (US) | 2022-07-28 | — | — | US | disclosed |
| US-20090099140-A1 | 20-Alkyl, Gemini Vitamin D3 Compounds and Methods of Use Thereof | BIOXELL S.P.A. (IT) | 2009-04-16 | — | — | US | disclosed |
| US-20090099140-A1 | 20-Alkyl, Gemini Vitamin D3 Compounds and Methods of Use Thereof | BIOXELL S.P.A. (IT) | 2009-04-16 | — | — | US | disclosed |
| US-20080293647-A1 | Combined Use Of Vitamin D Derivatives And Anti-Proliferative Agents For Treating Bladder Cancer | BIOXELL S.P.A. (IT) | 2008-11-27 | — | — | US | disclosed |
| US-20080280859-A1 | GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF | BIOXELL S.P.A. (IT) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280859-A1 | GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF | VDR, GC, CYP24A1 | VDR 1/4885MAPT 2629/4885ADORA3 57/4885 |
| US-20080293647-A1 | Combined Use Of Vitamin D Derivatives And Anti-Proliferative Agents For Treating Bladder Cancer | VDR, CYP24A1, CYP27B1 | VDR 1/4885MAPT 4682/4885ADORA3 1375/4885 |
| US-20090099140-A1 | 20-Alkyl, Gemini Vitamin D3 Compounds and Methods of Use Thereof | VDR, CYP24A1, CYP2R1 | VDR 1/4885MAPT 3551/4885ADORA3 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.